Researchers report that 1,5-pentanediamine—found in the blood of patients colonized with carbapenem-resistant Klebsiella pneumoniae—can weaken CD19 CAR-T cell activity in vitro. The study, published in Cancer Immunology, Immunotherapy, links a bacterial metabolite to reduced CAR-T function, pointing to a potential mechanistic barrier for patients with certain microbiome or colonization profiles. The finding is notable because it connects antimicrobial-resistance colonization with next-generation cell therapy performance. It suggests that CAR-T outcomes may depend not only on tumor and host immune status, but also on specific microbial metabolites present during treatment. For developers, it elevates the importance of infection control and microbiome-aware patient selection strategies in cell therapy protocols.